Plasma Fractionation Market by Product, Application, End-User

List of Tables

The Plasma Fractionation Market was valued at USD 35.52 billion in 2023, expected to reach USD 38.95 billion in 2024, and is projected to grow at a CAGR of 10.45%, to USD 71.27 billion by 2030.

Plasma fractionation refers to the process of separating and purifying components of plasma, primarily used in medical therapies. This includes proteins such as immunoglobulins, albumin, and clotting factors that are essential for various therapeutic applications in treating conditions like immune deficiencies, hemophilia, and autoimmune disorders. The necessity of plasma fractionation arises from the critical need for plasma-derived therapies to manage chronic ailments that cannot otherwise be treated effectively with synthetic alternatives. As such, the primary application involves medicinal use, especially for diseases requiring long-term treatment. End-use sectors mainly include hospitals, research institutions, and pharmaceutical companies. The market is significantly influenced by increasing demand for personalized medicine, advancements in healthcare infrastructure, and rising awareness about plasma therapies. Technological advancements like improved plasma purification processes and integration of artificial intelligence in diagnostics present potential opportunities for growth. Key recommendations to seize these opportunities include investing in R&D to enhance product efficacy and forming strategic alliances to streamline supply chain processes. However, the market is constrained by factors such as the high cost of plasma therapies, ethical concerns regarding plasma donation, and stringent regulatory requirements across different regions. Moreover, fluctuations in plasma supply due to donors' availability can pose challenges in meeting global demand. Companies seeking growth should focus on areas like enhancing donor recruitment strategies and developing synthetic or alternative protein substitutes that could alleviate supply issues. Innovation could also be directed towards improving fractionation technologies to boost yield and safety standards. Given the competitive nature of the market, a thorough understanding of regulatory landscapes, and continuous investment in technological upgrades are essential for sustained success. Emphasis on education and awareness campaigns can also help mitigate donation concerns, ultimately supporting market expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 35.52 billion
Estimated Year [2024]	USD 38.95 billion
Forecast Year [2030]	USD 71.27 billion
CAGR (%)	10.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Fractionation Market

The Plasma Fractionation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
- Government initiatives to increase plasma collection
- Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
Market Restraints
- Presence of new pathogenic agents that resist the present viral inactivation treatments
Market Opportunities
- Continuous advancements in process development technology for improved formulations
- Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
Market Challenges
- Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Fractionation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Fractionation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Fractionation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Fractionation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Fractionation Market

A detailed market share analysis in the Plasma Fractionation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Fractionation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Fractionation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Plasma Fractionation Market

A strategic analysis of the Plasma Fractionation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Albumin, Coagulation Factor Concentrates, Immunoglobulin, and Protease Inhibitors. The Coagulation Factor Concentrates is further studied across Factor IX, Factor VIII, Factor XIII, Fibrinogen Concentrates, Prothrombin Complex Concentrate, and Von Willebrand Factor. The Immunoglobulin is further studied across Intravenous Immunoglobulin and Subcutaneous Immunoglobulin.
Based on Application, market is studied across Critical Care, Hemato-Oncology, Hematology, Neurology, Pulmonology, and Rheumatology.
Based on End-User, market is studied across Academic & Research Institutes and Clinical Research Laboratories.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4312A385A58A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
  - 5.1.1.2. Government initiatives to increase plasma collection
  - 5.1.1.3. Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
- 5.1.2. Restraints
  - 5.1.2.1. Presence of new pathogenic agents that resist the present viral inactivation treatments
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous advancements in process development technology for improved formulations
  - 5.1.3.2. Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
- 5.1.4. Challenges
  - 5.1.4.1. Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising use of plasma fractionation for immunoglobulins purification
- 5.2.2. Application: Proliferating use to treat hematological disorders
- 5.2.3. End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Plasma Fractionation Market, by Product

6.1. Introduction
6.2. Albumin
6.3. Coagulation Factor Concentrates
- 6.3.1. Factor IX
- 6.3.2. Factor VIII
- 6.3.3. Factor XIII
- 6.3.4. Fibrinogen Concentrates
- 6.3.5. Prothrombin Complex Concentrate
- 6.3.6. Von Willebrand Factor
6.4. Immunoglobulin
- 6.4.1. Intravenous Immunoglobulin
- 6.4.2. Subcutaneous Immunoglobulin
6.5. Protease Inhibitors

7. Plasma Fractionation Market, by Application

7.1. Introduction
7.2. Critical Care
7.3. Hemato-Oncology
7.4. Hematology
7.5. Neurology
7.6. Pulmonology
7.7. Rheumatology

8. Plasma Fractionation Market, by End-User

8.1. Introduction
8.2. Academic & Research Institutes
8.3. Clinical Research Laboratories

9. Americas Plasma Fractionation Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Plasma Fractionation Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Plasma Fractionation Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
- 12.3.2. CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
- 12.3.3. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
- 12.3.4. Kedrion presented at plasma fractionation workshop in Saudi Arabia
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. 3M Company
2. ADMA Biologics, Inc.
3. Bharat Serums and Vaccines Limited
4. Bio Products Laboratory Ltd.
5. Biotest AG by Grifols, S.A.
6. China Biologic Products, Inc.
7. CSL Limited
8. Emergent BioSolutions Inc.
9. Fusion Health Care Pvt. Ltd.
10. GC Biopharma corp.
11. Grifols, S.A.
12. HEINKEL Process Technology GmbH
13. Hemarus Therapeutics Ltd
14. Intas Pharmaceuticals Ltd.
15. Kamada Ltd.
16. Kedrion S.p.A.
17. LFB SA
18. Merck KGaA
19. Octapharma AG
20. PlasmaGen BioSciences Pvt. Ltd.
21. Prothya Biosolutions B.V.
22. Sanquin
23. Shanghai Raas Blood Products Co. Ltd
24. SK Plasma Co.,Ltd.
25. STERIS plc
26. Takeda Pharmaceutical Company Ltd